infliximab

November 1, 2017

Effectiveness, Safety of Remicade’s Biosimilar, Inflectra, Confirmed in Phase 3 Trial

News

Switching Crohn’s disease patients from Remicade (infliximab) to its biosimilar Inflectra has no negative impact to treatment safety or effectiveness, a Phase 3 clinical trial shows. Pfizer and Celltrion Healthcare jointly presented those ... Read more

May 24, 2017

Miraca’s InformTx Treatment Response Platform for IBD Now Includes Testing for Inflectra

News

Miraca Life Sciences‘ InformTx testing helps doctors assess the response of patients with inflammatory bowel disease (IBD) to certain drug treatments. The company has now expanded its therapeutic drug monitoring ... Read more

May 22, 2017May 22, 2017

Switch From Remicade to Celltrion’s Biosimilar CT-P13 Safe in IBD, Clinical Trial Concludes

News

Patients with inflammatory bowel disease (IBD) may safely switch from Remicade (infliximab) to its biosimilar version CT-P13 — sold as Remsima and Inflectra — according to recently published clinical trial ... Read more

September 19, 2016September 19, 2016

Janssen to Monitor Remicade IBD Treatment for Free in Patients

News

Janssen Biotech is partnering with Miraca Life Sciences and its InformTx therapeutic drug monitoring service to develop the Janssen 2Inform program for patients with inflammatory bowel disease (IBD) being treated with Remicade ... Read more

June 9, 2016August 12, 2016

IBD Study Shows Celltrion’s Inflectra, Biosimilar of Infliximab, Is Safe and Effective

Crohn's Disease, IBD News, News, Ulcerative colitis

Celltrion’s Inflectra, a biosimilar version of infliximab (Remicade), is both safe and effective in patients with inflammatory bowel disease (IBD), a recent study reported at the Digestive Disease Week 2016 meeting ... Read more

May 2, 2016May 2, 2016

Certain Drug Therapies for Pregnant Women with IBD Can Have Impact on Newborns

News

Infants born to women who were treated with antibodies against tumor necrosis factor alpha (TNF alpha) during pregnancy have detectable levels of antibodies until 12 months of age, according to the results ... Read more

April 13, 2016September 28, 2016

Celltrion’s Inflectra, a Biosimilar to Treat Ulcerative Colitis and Crohn’s Disease, Gets FDA Approval

News

Celltrion recently announced it has received approval from the U.S. Food and Drug Administration (FDA) for the use of its Inflectra (biosimilar infliximab) product for all indications of the reference product, ... Read more

April 11, 2016April 11, 2016

FDA Approves Inflectra, a Biosimilar to Remicade, to Treat Ulcerative Colitis and Crohn’s

News

Celltrion announced that the U.S. Food and Drug Administration (FDA) approved Inflectra (biosimilar infliximab) for all indications of the reference product Remicade (infliximab), marketed in the country by Janssen Biotech, Inc. ... Read more